Tuttiquotidiani is completely free. Every day we aggregate news from 100+ sources and generate original AI summaries for you. Help us keep the service running with a small donation, or become TQ Pro for just €1/month.

Donate now TQ Pro - 1€/mo

FDA Extends Review of Eisai, Biogen Alzheimer's Drug

Posted on May 9, 2026
By International Business Times
0 Views
1 min read

FDA Extends Review of Eisai, Biogen Alzheimer's Drug

The agency pushed its decision on weekly subcutaneous LEQEMBI IQLIK for early Alzheimer's initial treatment to Aug. 24 after seeking additional information.